Related Experiment Video

Updated: Sep 21, 2026

Barnes Maze Testing Strategies with Small and Large Rodent Models
12:59

Barnes Maze Testing Strategies with Small and Large Rodent Models

Published on: February 26, 2014

44.2K

DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild

Leonidas Chouliaras1, Gunter Kenis1, Pieter Jelle Visser1,2

  • 1Department of Psychiatry & Neuropsychology, School for Mental Health & Neuroscience, European Graduate School of Neuroscience (EURON), Maastricht University Medical Centre, Maastricht, The Netherlands.

Epigenomics
|June 26, 2015
PubMed

Insights

Common genetic variations in DNA methylation genes may influence cognitive decline in individuals with mild cognitive impairment. A specific SNP in DNMT3A was linked to faster annual cognitive decline, suggesting a role in Alzheimer's disease progression.

Area of Science:

  • Neuroscience
  • Genetics
  • Epigenetics

Background:

  • Epigenetic alterations, particularly DNA methylation changes, are implicated in cognitive decline and Alzheimer's disease.
  • Mild cognitive impairment (MCI) is a transitional stage between normal aging and dementia, making it a critical period for studying disease mechanisms.

Purpose of the Study:

  • To investigate the association between single nucleotide polymorphisms (SNPs) in DNA methylation-regulating genes and age-related cognitive decline in MCI patients.
  • To identify specific genetic markers that may predict or moderate cognitive decline in individuals with MCI.

Main Methods:

  • The study analyzed common SNPs in genes involved in DNA methylation across two independent prospective cohorts of patients diagnosed with mild cognitive impairment.
  • Cognitive functioning was assessed annually to track age-related changes.
  • Statistical analyses were performed to determine associations between specific SNPs and the rate of cognitive decline.

Main Results:

  • A significant association was found between the rs1187120 SNP located in the DNMT3A gene and the annual rate of cognitive decline.
  • This association was successfully replicated in both independent patient cohorts, strengthening the finding.
  • The results suggest that variations in DNMT3A may play a moderating role in cognitive decline among individuals with MCI.

Conclusions:

  • The rs1187120 SNP in the DNMT3A gene is associated with accelerated cognitive decline in patients with mild cognitive impairment.
  • DNMT3A may represent a novel genetic target for understanding and potentially mitigating cognitive decline in the context of neurodegenerative diseases like Alzheimer's.
Keywords:
DNA methylationDNMT3AMCISNPagingepigeneticsmild cognitive impairment

More Related Videos

Traditional Trail Making Test Modified into Brand-new Assessment Tools: Digital and Walking Trail Making Test08:07

Traditional Trail Making Test Modified into Brand-new Assessment Tools: Digital and Walking Trail Making Test

Published on: November 23, 2019

12.0K
Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

787

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...